敗血症診断の世界市場予測（～2021年）...市場調査レポートについてご紹介

1 Introduction (Page No. – 17)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.4 Markets Covered
1.4.1 Years Considered for the Study
1.5 Currency
1.6 Limitations
1.7 Stakeholders

2 Research Methodology (Page No. – 20)
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.3 Market Size Estimation Methodology
2.1.3.1 Bottom-Up Approach
2.1.3.2 Top-Down Approach
2.1.4 Research Design
2.1.5 Market Data Validation and Triangulation
2.1.6 Assumptions for the Study

3 Executive Summary (Page No. – 29)
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook
3.4 Conclusion

4 Premium Insights (Page No. – 34)
4.1 Attractive Market Opportunities in the Global Sepsis Diagnostics
4.2 Geographic Analysis: Sepsis Diagnostics Market, By Product
4.3 Sepsis Diagnostics Market Size, By Technology, 2016 vs 2021
4.4 Sepsis Diagnostics Market Size, By Method and Region, 2016
4.5 Sepsis Diagnostics Market Size, By USAbility, 2016 vs 2021
4.6 Sepsis Diagnostics Market Size, By Pathogen, 2016 vs 2021

5 Market Overview (Page No. – 39)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 High Prevalence of Sepsis in the Neonate and Adult Population
5.2.1.2 Rising Incidence of Sepsis in Geriatric Population
5.2.1.3 Increasing Number of Preterm Births
5.2.1.4 Growing Incidence of Hospital-Acquired Infections
5.2.1.5 Increasing Number of Surgical Procedures
5.2.1.6 Growing Pneumonia Cases
5.2.1.7 Influx of Novel Sepsis Diagnostic Products
5.2.2 Restraints
5.2.2.1 High Cost of Automated Diagnostic Devices
5.2.2.2 Lack of Established Reimbursement for Sepsis
5.2.3 Opportunities
5.2.3.1 Increasing Funding for Sepsis-Related Research Activities
5.2.3.2 Development of Rapid Diagnostic Techniques for Early Sepsis Diagnosis
5.2.3.3 Evolution of Procalcitonin Test as A Novel Biomarker for Sepsis Diagnosis
5.2.3.4 Rising Initiatives to Increase the Awareness and Drive the Adoption of Sepsis Diagnostic Tests
5.2.3.5 Growing Number of Regulatory Approvals for Sepsis Diagnostic Products
5.2.4 Challenges
5.2.4.1 Lack of Standard Protocols and Awareness for Sepsis Diagnosis and Treatment
5.2.4.2 Shortage of Skilled Healthcare Professionals

6 Sepsis Diagnostics Market, By Product (Page No. – 49)
6.1 Introduction
6.2 Instruments
6.3 Blood Culture Media
6.4 Assay Kits & Reagents
6.5 Software

7 Sepsis Diagnostics Market, By Technology (Page No. – 57)
7.1 Introduction
7.2 Microbiology
7.3 Molecular Diagnostics
7.4 Immunoassays
7.5 Flow Cytometry

8 Sepsis Diagnostics Market, By Method (Page No. – 66)
8.1 Introduction
8.2 Conventional Diagnostics
8.3 Automated Diagnostics

9 Sepsis Diagnostics Market, By USAbility (Page No. – 72)
9.1 Introduction
9.2 Laboratory Testing
9.3 Point-Of-Care Testing

10 Sepsis Diagnostics Market, By Pathogen (Page No. – 78)
10.1 Introduction
10.2 Bacterial Sepsis
10.2.1 Gram-Negative Bacterial Sepsis
10.2.2 Gram-Positive Bacterial Sepsis
10.3 Fungal Sepsis
10.4 Other Pathogen Infections

11 Sepsis Diagnostics Market, By Region (Page No. – 86)
11.1 Introduction
11.2 North America
11.2.1 U.S.
11.2.1.1 Growing Prevalence of Sepsis
11.2.1.2 Increasing Incidences of Hais
11.2.1.3 Increasing Government Support for Sepsis Research
11.2.1.4 Growing Product Approvals
11.2.1.5 Rising Initiatives to Drive the Adoption of Sepsis Diagnostic Tools
11.2.1.6 Lack of Standard Protocol for Sepsis Diagnosis Hinders Market Growth
11.2.1.7 High Cost of Treatment
11.2.2 Canada
11.2.2.1 Expanding Patient Population Base
11.2.2.2 Support for the Development of Novel Sepsis Diagnostic Products
11.2.2.3 Growing Focus on Sepsis Management
11.2.2.4 Low Awareness Related to Sepsis Management
11.2.2.5 Dearth of Training Leading to Inadequate Patient Assessment
11.3 Europe
11.3.1 Germany
11.3.1.1 High Incidence of Sepsis
11.3.1.2 Growing Funding for Sepsis Research
11.3.1.3 Initiatives By the German Sepsis Society
11.3.1.4 High Awareness Related to the Sepsis Management
11.3.1.5 Development of Novel Sepsis Diagnostics Products
11.3.1.6 Poor Implementation of Guidelines Related to the Sepsis Management
11.3.2 U.K.
11.3.2.1 Growing Initiatives By Government Organizations
11.3.2.2 Increasing Awareness Among Medical Staff and General Practitioners
11.3.2.3 Rising Focus Towards the Development of New Sepsis Diagnostics Devices
11.3.2.4 Rising Demand for Diagnostic Devices
11.3.2.5 Dearth of Paramedics
11.3.3 France
11.3.3.1 Growing Number of Symposiums and Conferences
11.3.3.2 High Prevalence of Sepsis
11.3.3.3 Growth in Research Funding for Sepsis Diagnosis
11.3.4 Rest of Europe (RoE)
11.3.4.1 Hub for Various Sepsis Related Conferences
11.3.4.2 Rapid Growth in the Aging Population
11.3.4.3 Initiatives to Diagnose Neonatal Sepsis
11.3.4.4 Rising Focus on the Development of Advanced Products
11.4 Asia-Pacific
11.4.1 Japan
11.4.1.1 Increasing Incidence of Healthcare-Associated Infections
11.4.1.2 Growing Aging Population
11.4.1.3 Increasing Initiatives By Market Players
11.4.1.4 Lack of Proper Reimbursement for Sepsis
11.4.2 China
11.4.2.1 Large Number of Ongoing Clinical Studies
11.4.2.2 Developing Healthcare Infrastructure
11.4.2.3 Limited Implementation of Surviving Sepsis Campaign (SSC)
11.4.3 India
11.4.3.1 High Sepsis Burden
11.4.3.2 Rising Antibiotic Resistance
11.4.3.3 Rising Number of Icu Patients
11.4.3.4 Increasing Number of Surgical Procedures
11.4.3.5 Rising Focus of Local and Global Players
11.4.3.6 Shortage of Medical Staff in India
11.4.3.7 Lack of Awareness Leading to Death Due to Sepsis
11.4.4 Rest of Asia-Pacific
11.4.4.1 Large Number of Ongoing Conferences
11.4.4.2 Rising Initiatives to Increase Awareness About Sepsis
11.4.4.3 Significant Patient Population Base in Malaysia
11.4.4.4 South Korea Presents Significant Growth Opportunities
11.4.4.5 Lack of Established Sepsis Management Guidelines
11.4.4.6 Lack of Reimbursement for Sepsis
11.5 Rest of the World
11.5.1.1 Increasing Antibiotic Resistance Among Patients
11.5.1.2 Initiatives to Improve Healthcare in Middle East Countries
11.5.1.3 High Prevalence of Cancer and Hiv in the Region
11.5.1.4 Key Challenges to Market Growth in the Region

12 Competitive Landscape (Page No. – 135)
12.1 Overview
12.2 Market Share Analysis
12.3 Competitive Situation and Trends
12.3.1 Product Approvals
12.3.2 Collaborations, Acquisitions, and Partnerships
12.3.3 New Product Launches
12.3.4 Other Strategies

13 Company Profiles (Page No. – 141)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
13.1 Introduction
13.2 Biomérieux SA
13.3 Becton, Dickinson and Company
13.4 Thermo Fisher Scientific Inc.
13.5 Abbott Laboratories, Inc.
13.6 Roche Diagnostics Limited (A Subsidiary of F. Hoffmann-La Roche Ltd.)
13.7 Cepheid Inc.
13.8 T2 Biosystems, Inc.
13.9 Beckman Coulter, Inc. (A Subsidiary of Danaher Corporation)
13.10 Nanosphere, Inc. (A Luminex Company)
13.11 Bruker Corporation

*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

14 Appendix (Page No. – 165)
14.1 Discussion Guide
14.2 Other Developments
14.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
14.4 Introducing RT : Real-Time Market Intelligence
14.5 Available Customizations
14.6 Related Reports